announcement coming, page-24

From the Philips HHD Clinical Study Manager position description:

"The Point of Care market is around $5.4 billion and growing at 6%. Cardiac point of care is a significant segment at around $680 million and growing at 9%.The first focus of the venture is to launch two important Cardiac Markers (cardiac Troponin-I and BNP) on the Minicare system"

From the ann re PoC1:
"The challenge is compounded as our partner has restricted our activities to one part of the system for the present study. Despite this we continue to demonstrate the ease and simplicity of Mix&Go in the development program."

So, could it be that Philips have limited our focus to Troponin so they can be 1st to market and launch the Minicare system? Regardless, it appears M&G is handling the challenge well...

.connect.connect.connect.